- Home
- PETS vs BCAB Comparison
PETS vs BCAB Comparison
Compare PETS & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- BCAB
- Stock Information
- Founded
- PETS 1996
- BCAB 2007
- Country
- PETS United States
- BCAB United States
- Employees
- PETS N/A
- BCAB N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- PETS Consumer Staples
- BCAB Health Care
- Exchange
- PETS Nasdaq
- BCAB Nasdaq
- Market Cap
- PETS 82.0M
- BCAB 91.4M
- IPO Year
- PETS N/A
- BCAB 2020
- Fundamental
- Price
- PETS $3.98
- BCAB $1.95
- Analyst Decision
- PETS Sell
- BCAB Strong Buy
- Analyst Count
- PETS 2
- BCAB 2
- Target Price
- PETS $3.50
- BCAB $6.00
- AVG Volume (30 Days)
- PETS 174.8K
- BCAB 2.0M
- Earning Date
- PETS 10-28-2024
- BCAB 11-05-2024
- Dividend Yield
- PETS 28.95%
- BCAB N/A
- EPS Growth
- PETS N/A
- BCAB N/A
- EPS
- PETS N/A
- BCAB N/A
- Revenue
- PETS $270,772,000.00
- BCAB N/A
- Revenue This Year
- PETS N/A
- BCAB N/A
- Revenue Next Year
- PETS $3.27
- BCAB N/A
- P/E Ratio
- PETS N/A
- BCAB N/A
- Revenue Growth
- PETS 2.26
- BCAB N/A
- 52 Week Low
- PETS $2.90
- BCAB $1.14
- 52 Week High
- PETS $10.53
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- PETS 54.93
- BCAB 52.96
- Support Level
- PETS $3.89
- BCAB $1.86
- Resistance Level
- PETS $4.22
- BCAB $2.00
- Average True Range (ATR)
- PETS 0.20
- BCAB 0.17
- MACD
- PETS -0.02
- BCAB -0.01
- Stochastic Oscillator
- PETS 47.37
- BCAB 22.14
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.